

DAFTAR PUSTAKA

1. Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. Jakarta: PB PERKENI; 2021. 1–119 p.
2. American Diabetes Association. Standards of Medical Care in Diabetes. Vol. 40. USA: Diabetes Care; 2017. 1–142 p.
3. Rapuano CJ, Stout JT, McCannel CA. Retinal Vascular Disease: Diabetic Retinopathy. In: Retina and Vitreous. Retina and Vitreous. San Fransisco: American Academy of Ophthalmology; 2020. p. 91–116.
4. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. *Ophthalmology*. 2021 Nov 1;128(11):1580–91.
5. Naserrudin NA, Jeffree MS, Kaur N, Rahim SSSA, Ibrahim MY. Diabetic Retinopathy among Type 2 Diabetes Mellitus Patients in Sabah Primary Health Clinics-Addressing the Underlying Factors. *PLoS One*. 2022 Jan 1;17(1):1–11.
6. Raja SA, Chong VH, Rahman NA, Shakir LMP, Knights J. Prevalence and Associated Factors of Diabetic Retinopathy among Type 2 Diabetes Mellitus Patients in Brunei Darussalam: A Cross-sectional Study. *Korean Journal of Ophthalmology*. 2022 Feb 1;36(1):26–35.
7. Halim A, Rini M, Ratnaningsih N, Iskandar E, Sovani I, Virgana R, et al. Prevalence and Associated Factors of Diabetic Retinopathy in People with Type 2 Diabetes Attending Community Based Diabetic Retinopathy Screening in Greater Bandung. *International Journal of Retina*. 2022;5(1):1–9.
8. Sasongko MB, Widyaputri F, Agni AN, Wardhana FS, Kotha S, Gupta P, et al. Prevalence of Diabetic Retinopathy and Blindness in Indonesian Adults With Type 2 Diabetes. *Am J Ophthalmol*. 2017 Sep 1;181:79–87.
9. Bhavsar A, Atebara N, Drouilhet J. Diabetic Retinopathy [Internet]. *Medscape*. 2021 [cited 2022 Jul 23]. Available from: <https://emedicine.medscape.com/article/1225122-overview>
10. Cecilia OM, Jose Alberto CG, Jose NP, Ernesto German CM, Ana Karen LC, Luis Miguel RP, et al. Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology. *Journal of Diabetes Research*. Hindawi Limited; 2019. p. 1–21.
11. Grigsby JG, Allen DM, Ferrigno AS, Vellanki S, Pouw CE, Hejny WA, et al. Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina. *Curr Diabetes Rev*. 2017;13:161–74.

12. Wang J, Chen S, Jiang F, You C, Mao C, Yu J, et al. Vitreous and Plasma VEGF Levels as Predictive Factors in the Progression of Proliferative Diabetic Retinopathy After Vitrectomy. *PLoS One*. 2014 Oct 16;9(10):1–8.
13. Valle MS, Russo C, Malaguarnera L. Protective Role of Vitamin D Against Oxidative Stress in Diabetic Retinopathy. *Diabetes Metab Res Rev*. 2021 Nov 1;37(8):1–18.
14. Chan HN, Zhang XJ, Ling XT, Bui CHT, Wang YM, Ip P, et al. Vitamin D and Ocular Diseases: A Systematic Review. Vol. 23, *International Journal of Molecular Sciences*. MDPI; 2022. p. 1–58.
15. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, et al. Calcitriol is a Potent Inhibitor of Retinal Neovascularization. *Invest Ophthalmol Vis Sci*. 2007 May;48(5):2327–34.
16. Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 Protects Against Diabetic Retinopathy by Inhibiting High-Glucose-induced Activation of the ROS/TXNIP/NLRP3 Inflammasome pathway. *J Diabetes Res*. 2018;1–11.
17. Ren Z, Li W, Zhao Q, Ma L, Zhu J. The Impact of 1,25-dihydroxy Vitamin D3 on the Expressions of Vascular Endothelial Growth Factor and Transforming Growth Factor- β 1 in the Retinas of Rats with Diabetes. *Diabetes Res Clin Pract*. 2012 Dec;98(3):474–80.
18. Rapuano C, Stout J, McCannel C. Vitreous. In: *Fundamentals and Principles of Ophthalmology*. San Fransisco: American Academy of Ophthalmology; 2020. p. 295–304.
19. Rapuano CJ, Stout JT, McCannel CA. Basic Anatomy. In: *Retina and Vitreous*. San Fransisco: American Academy of Ophthalmology; 2020. p. 7–20.
20. Khurana AK. Disease of Retina. In: *Comprehensive Ophthalmology*. New Delhi: Jaypee Brothers Medical Publisher; 2007. p. 271–98.
21. Rapuano CJ, Stout JT, McCannel CA. Retina. In: *Fundamentals and Principles of Ophthalmology*. San Fransisco: American Academy of Ophthalmology; 2020. p. 305–19.
22. Rapuano CJ, Stout JT, McCannel CA. The Eye. In: *Fundamentals and Principles of Ophthalmology*. San Fransisco: American Academy of Ophthalmology; 2020. p. 83–103.
23. Siemerink MJ, Augustin AJ, Schlingemann RO. Mechanisms of Ocular Angiogenesis and Its Molecular Mediators. *Dev Ophthalmol Basel*, Karger. 2010;46:4–20.
24. Rapuano CJ, Stout JT, McCannel CA. Retinal Pigment Epithelium. In: *Fundamentals and Principles of Ophthalmology*. San Fransisco: American Academy of Ophthalmology; 2020. p. 321–32.
25. Safi SZ, Qvist R, Kumar S, Batumalaie K, Ismail IS bin. Molecular Mechanisms of Diabetic Retinopathy, General Preventive Strategies, and Novel Therapeutic Targets. *Biomed Res Int*. 2014;1–19.

26. Shin ES, Sorenson CM, Sheibani N. Diabetes and Retinal Vascular Dysfunction. *J Ophthalmic Vis Res.* 2014 Jul 1;9(3):362–73.
27. Kang Q, Yang C. Oxidative Stress and Diabetic Retinopathy: Molecular Mechanisms, Pathogenetic Role and Therapeutic Implications. *Redox Biol.* 2020 Oct 1;37:1–17.
28. Kowluru RA, Mishra M. Oxidative Stress, Mitochondrial Damage and Diabetic Retinopathy. *Biochim Biophys Acta Mol Basis Dis.* 2015 Nov 1;1852(11):2474–83.
29. Brownlee M. Biochemistry and Molecular Cell Biology of Diabetic Complication. *Insight Review Articles [Internet].* 2001;414:813–20. Available from: www.nature.com
30. Santos JM, Tewari S, Lin JY, Kowluru RA. Interrelationship Between Activation of Matrix Metalloproteinases and Mitochondrial Dysfunction in the Development of Diabetic Retinopathy. *Biochem Biophys Res Commun.* 2013 Sep 6;438(4):760–4.
31. Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic Retinopathy and VEGF. *Open Ophthalmol J.* 2013;7:4–10.
32. De Groot H, Schmit-Eilenberger V, Kirchhof J, Augustin AJ. Angiostatic and Angiogenic Factors. *Dev Ophthalmol Basel, Karger.* 2010;46:1–3.
33. Caprnda M, Kubatka P, Saxena S, Valaskova J, Stefanickova J, Kobylak N, et al. The Impact of Hyperglycemia on VEGF Secretion in Retinal Endothelial Cells. *Folia Med (Plovdiv).* 2017 Jun 1;59(2):183–9.
34. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, et al. Vascular Endothelial Growth Factor and Diabetic Retinopathy: Pathophysiological Mechanisms and Treatment Perspectives. *Diabetes Metab Res Rev.* 2003 Nov;19(6):442–55.
35. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular Endothelial Growth Factor in Eye Disease. *Prog Retin Eye Res.* 2008 Jul;27(4):331–71.
36. Al-Shabrawey M, Elsherbiny M, Nussbaum J, Othman A, Megyerdi S, Tawfik A. Targeting Neovascularization in Ischemic Retinopathy: Recent Advances. *Expert Rev Ophthalmol.* 2013;8(3):267–86.
37. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of Memantine on Neuroretinal Function and Retinal Vascular Changes of Streptozotocin-induced Diabetic Rats. *Invest Ophthalmol Vis Sci.* 2007 Nov;48(11):5152–9.
38. Kusari J, Zhou SX, Padillo E, Clarke KG, Gil DW. Inhibition of Vitreoretinal VEGF Elevation and Blood-Retinal Barrier Breakdown in Streptozotocin-induced Diabetic Rats by Brimonidine. *Invest Ophthalmol Vis Sci.* 2010 Feb;51(2):1044–51.

39. Tecilizich F, Formenti AM, Giustina A. Role of Vitamin D in Diabetic Retinopathy: Pathophysiological and Clinical Aspects. *Rev Endocr Metab Disord*. 2021 Dec 1;22(4):715–27.
40. Neyestani TR. Vitamin D, Oxidative Stress and Diabetes: Is There A Link? In: *Diabetes: Oxidative Stress and Dietary Antioxidants*. Elsevier Inc.; 2013. p. 111–20.
41. Alatawi FS, Faridi UA, Alatawi MS. Effect of Treatment with Vitamin D Plus Calcium on Oxidative Stress in Streptozotocin-induced Diabetic Rats. *Saudi Pharmaceutical Journal*. 2018 Dec 1;26(8):1208–13.
42. Fernandez-Robredo P, González-Zamora J, Recalde S, Bilbao-Malavé V, Bezunartea J, Hernandez M, et al. Vitamin D Protects Against Oxidative Stress and Inflammation in Human Retinal Cells. *Antioxidants*. 2020 Sep 1;9(9):1–18.
43. Jamali N, Wang S, Darjatmoko SR, Sorenson CM, Sheibani N. Vitamin D Receptor Expression is Essential During Retinal Vascular Development and Attenuation of Neovascularization by 1, 25(OH)2D3. *PLoS One*. 2017 Dec 1;12(12):1–20.
44. Gkoutinakou IM, Kechagia E, Pazaitou-Panayiotou K, Mylonis I, Liakos P, Tsakalof A. Calcitriol Suppresses HIF-1 and HIF-2 Transcriptional Activity by Reducing HIF-1/2 α Protein Levels via a VDR-Independent Mechanism. *Cells*. 2020 Nov 9;9(11):1–21.
45. Li C, Miao X, Li F, Wang S, Liu Q, Wang Y, et al. Oxidative Stress-Related Mechanisms and Antioxidant Therapy in Diabetic Retinopathy. *Oxid Med Cell Longev*. 2017;1–16.
46. Garcia-Medina JJ, Rubio-Velazquez E, Foulquie-Moreno E, Casaroli-Marano RP, Pinazo-Duran MD, Zanon-Moreno V, et al. Update on the Effects of Antioxidants on Diabetic Retinopathy: in Vitro Experiments, Animal Studies and Clinical Trials. *Antioxidants*. 2020;9(6):1–23.
47. Lai AKW, Lo ACY. Animal Models of Diabetic Retinopathy: Summary and Comparison. *J Diabetes Res*. 2013;1–29.
48. Pitale PM, Gorbatyuk MS. Diabetic Retinopathy: From Animal Models to Cellular Signaling. *Int J Mol Sci*. 2022 Feb 1;23(3):1–22.
49. Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. *Curr Protoc*. 2021 Apr 1;1(4):1–21.
50. Wu KK, Huan Y. Streptozotocin-induced Diabetic Models in Mice and Rats. *Curr Protoc Pharmacol*. 2008;40:1–14.
51. Chen M, Stitt A. Animal Models of Diabetic Retinopathy. In: *Animal Models of Ophthalmic Diseases*. New York: Springer; 2016. p 67-79.

52. Kim YS, Sohn EJ, Kim CS, Lee YM, Jung DH, et al. Vascular Endothelial Growth Factor (VEGF) and Advanced Glycation End Products (AGEs) Overexpression in the Retina and Serum and Lens Opacities of Streptozotocin induced Diabetic Rats. *Korean Diabetes Journal*. 2008;32:44-52.
53. Patil MA, Palla S, Uday KP, et al. Evaluation of Neonatal Streptozotocin Induced Diabetic Rat Model. *Oxidative Medicine and Cellular Longevity* 2014. p. 1-11.
54. Gong X, Qiuyan Z, Shuhua T. Inhibitory Effect of r-Hirudin Variant III on Streptozotocin-Induced Diabetic in Rats. *Hindawi Publishing Corporation The Scientific World Journal*. 2013. p. 1-8.
55. Caban M, Lewandowska U. Vitamin D, the vitamin D receptor, Calcitriol Analogues and Their Link with Ocular Disease. *Nutrients*. 2022 Jun 5;14(11):2353.
56. Skowron K, Pawlicka I, Gil K. The role of vitamin D in the pathogenesis of ocular diseases. *Folia Med Cracov*. 2018;LVIII(2):103118.
57. Almoosa A, Ayachit S, Doms P, Aldoseri A, Wagih W. Incidence of Vitamin D Deficiency in Patients with Type II Diabetes Mellitus and its Relation to the Severity of Retinopathy. *Bahrain Medical Bulletin*. 2019;41(4):238-240.
58. Robinson J, Manson J, Larson J, Liu S, Song Y, Howard B, et al. Lack of association between 25 (OH) D levels and incident type 2 diabetes in older women. *Diabetes Care*. 2011;34(3):628-634.
59. Zoppini G, Galletti A, Targher G, Brangani C, Pichiri I, Trombetta M, et al. Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes. *BMJ Open Diabetes Research and Care*. 2015;3(1):e000058.
60. Palazhy S, Viswanathan V, Muruganathan A. Prevalence of 25-hydroxy vitamin D deficiency among type 2 diabetic subjects of South India. *International Journal of Diabetes in Developing Countries*. 2017;37(1):69- 73.